Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494366 | 0.88 | TEAD1 (0.50) | KDM4EMAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4286026 | 0.88 | HPGD (0.49) | KDM4EMAPTPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4281940 | 0.88 | KCNA5 (0.46) | HTTALDH1A1RAB9AKCNA5 | |
| SCHEMBL4295523 | 0.88 | HCRTR1 (0.36) | HCRTR1HCRTR2KDM4EHTTMAPT | |
| SCHEMBL4281983 | 0.88 | L3MBTL1 (0.48) | KDM4EHTTMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4285825 | 0.86 | KCNA5 (0.49) | HCRTR1HCRTR2MAPTALDH1A1KCNA5 | |
| SCHEMBL4290686 | 0.86 | ENPP2 (0.43) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL4294542 | 0.85 | KDM4E (0.49) | KDM4EMAPTALDH1A1GAA | |
| SCHEMBL4287459 | 0.84 | KMT2A (0.49) | KDM4EPOLBSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4295216 | 0.84 | KMT2A (0.49) | KDM4EMAPTALDH1A1RAB9AFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885KDM4E 760/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885KDM4E 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.